Helmy Eltoukhy

{{short description|American scientist and entrepreneur|bot=PearBOT 5}}

{{ambox|issue=This article is written like an advertisement. |fix=To meet Wikipedia's quality standards and comply with Wikipedia's neutral point of view policy, it may require substantial cleanup.|type=content| date=February 2025}}

{{COI|date=February 2025}}

{{Infobox scientist

| honorific_prefix =

| name = Helmy Eltoukhy

| honorific_suffix =

| native_name =

| native_name_lang =

| image = Helmy Eltoukhy.jpg

| image_size =

| image_upright =

| alt =

| caption =

| birth_name =

| birth_date =

| birth_place =

| death_date =

| death_place =

| death_cause =

| resting_place =

| resting_place_coordinates =

| home_town =

| other_names =

| pronounce =

| residence =

| citizenship =

| nationality =

| fields = Genomics
Electrical engineering

| workplaces =

| patrons =

| education =

| alma_mater = Stanford University
{{small|BS, Electrical engineering }}
{{small|MS, Electrical engineering}}
{{small|PhD, Electrical engineering}}
Stanford Genome Technology Center {{small|(Postdoc)}}

| thesis_title = An integrated system for de novo DNA sequencing

| thesis_url =

| thesis_year =

| doctoral_advisor = Abbas El Gamal{{cite web |url=http://isl.stanford.edu/~abbas/aegstudents.php |title=Stanford Engineering, Abbas El Gamal - Previous Students |author= |date= 2019|website= Stanford University|access-date=5 Nov 2019 }}{{cite news |last= Shinal|first= John|date=20 Feb 2015 |title=More-accurate cancer tests based on computer math |url=https://www.usatoday.com/story/tech/2015/02/20/new-tech-economy-cancer-research/23740901/ |work=USA Today |access-date=5 Nov 2019 }}

| academic_advisors =

| doctoral_students =

| notable_students =

| known_for = Co-Founder & CEO, Guardant Health
Co-Founder & CEO, Avantome

| influences =

| influenced =

| awards =

| author_abbrev_bot =

| author_abbrev_zoo =

| spouse = Carson Eltoukhy (? - 2020)

| partner =

| children =

| signature =

| signature_alt =

| website =

| footnotes =

}}

Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.{{cite book|author1=Harry Glorikian|author2=Malorye Allison Branca|title=MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market|chapter-url=https://books.google.com/books?id=foY_DwAAQBAJ&pg=PT110|access-date=19 October 2019|date=20 November 2017|publisher=Taylor & Francis|isbn=978-1-351-98433-1|pages=110–|chapter=Liquid Biopsies}}

Education

Eltoukhy attended Bellarmine College Preparatory, studying college level math during his freshman year, and graduating in 1997.{{cite web |url=https://www.instagram.com/bellarminebells/p/BDSCgaKvRra/ |title=BellarmineBells |author= |date=23 Mar 2016 |website=Instagram |publisher=Bellarmine College Preparatory |access-date=19 Nov 2019 }} Subsequently, Eltoukhy studied electrical engineering at Stanford University, completing an accelerated Bachelor of Science (BS) in two and a half years,{{cite magazine |last=Hindery |first=Robin |date=2015 |title=Keeping Pace with Cancer: Helmy Eltoukhy's startup, Guardant Health, is making waves in the healthcare world by using cutting-edge DNA sequencing technology to track cancer in real time |url=https://mydigitalpublication.com/publication/?i=250930&ver=html5&p=10#{%22issue_id%22:%22250930%22,%22page%22:10} |magazine=Gentry Health |location=California, USA |publisher=The Golden State Company |access-date=19 Nov 2019 |pages=108–109 }} followed by Master of Science (MS) and Doctorate (PhD) degrees. Eltoukhy’s doctoral thesis, “An integrated system for de novo DNA sequencing” research was completed in the laboratory of Abbas El Gamal, for a project that combined genomics and sensor engineering.{{cite news |date= 29 Jul 2008|title=Illumina to Buy Avantome for Up to $60M; Long, Cheap Reads Will Target Sanger |url=https://www.genomeweb.com/sequencing/illumina-buy-avantome-60m-long-cheap-reads-will-target-sanger#.Xa8fLehKjb0 |work=genomeweb.com }}{{cite thesis |last= Eltoukhy|first=Helmy |date=2006 |title= An integrated system for de novo DNA sequencing|publisher=Stanford University |oclc=71209106}}{{cite book|author1=Dan V. Nicolau|author2=Ramesh Raghavachari|author3=Society of Photo-optical Instrumentation Engineers|title=Microarrays and combinatorial technologies for biomedical applications: design, fabrication, and analysis |url=https://books.google.com/books?id=YNNTAAAAMAAJ|access-date=22 October 2019|year=2003|publisher=SPIE|isbn=978-0-8194-4766-1|chapter=Modeling and simulation of luminescence detection platforms (Salama K, Eltoukhy H, Hassabi A, and El-Gamal A)}} Eltoukhy discovered that low cost CMOS image sensors coupled to light-emitting DNA sequencing reactions could form the basis for building a less expensive, portable DNA sequencer.

Career

=Genome Technology Center=

After graduation, Eltoukhy completed a post-doctoral fellowship at Stanford University’s Genome Technology Center, investigating low-cost DNA sequencing technologies as part of the Human Genome Project.{{cite web|url=http://www.genome.gov/11006943| title=Human Genome Project Completion: Frequently Asked Questions|website=genome.gov|publisher=National Human Genome Research Institute|access-date=22 Oct 2019}} Eltoukhy’s research focused on developing new assays and detection methods, with an emphasis on semiconductor-based approaches for DNA sequencing. That research was funded, in part, by one of the first National Human Genome Research Institute grants awarded for massive parallel sequencing (also known as Next Generation Sequencing or NGS).{{cite web |url=https://www.genome.gov/12513210/2004-release-nhgri-seeks-next-generation-of-sequencing-technologies |title=NHGRI Seeks Next Generation of Sequencing Technologies |author= |date= 14 Oct 2004|website=genome.gov |access-date=22 Oct 2019 |quote=Mostafa Ronaghi, Stanford Genome Technology Center, $1.8 million (3 years) "Pyrosequencing Array for DNA Sequencing"}}{{cite AV media |people=Ron Kerr, Helmy Eltoukhy, Bambi Francisco |date=23 Feb 2016 |title=$1,000 is the "right price" for human genome |medium=video |language=en |url=https://vator.tv/news/2016-02-23-1000-is-the-right-price-for-human-genome |access-date= 22 Oct 2019|publisher=Vator }}

=Avantome and Illumina=

In 2007, Eltoukhy and Mostafa Ronaghi co-founded the biotechnology startup company Avantome, to accelerate the commercialization of semiconductor sequencing technologies and affordable high-throughput DNA sequencing.{{cite web |url=https://www.fiercebiotech.com/biotech/illumina-snares-sequencing-tech-60m-buyout |title=Illumina snares sequencing tech in $60M buyout |first=John |last=Carroll|date=23 Jul 2008 |website= fiercebiotech.com|publisher=Questex, LLC |access-date= 19 Oct 2019}} Eltoukhy was president and CEO of the new company until 2008, when Avantome was acquired by Illumina.{{cite news |author= |date=11 Jan 2016 |title= Illumina Unveils Mini Targeted Sequencer, Semiconductor Sequencing Project at JP Morgan Conference|url=https://www.genomeweb.com/sequencing-technology/illumina-unveils-mini-targeted-sequencer-semiconductor-sequencing-project-jp#.Xa8fK-hKjb0 |work=GenomeWeb |location=USA |access-date=16 Oct 2019 }} As part of the acquisition terms, Ronaghi and Eltoukhy joined Illumina, where Eltoukhy continued pioneering genomic research as director of Advanced Sequencing Development until 2012. At Illumina, Avantome’s CMOS/semiconductor sequencing platform became the basis for Project Firefly, a program to develop an "integrated sequencing solution simple and affordable enough to install in hospitals for routine testing".{{cite news |author= |date=12 Feb 2016 |title=At AGBT, Illumina Provides Additional Details on Project Firefly |url=https://www.genomeweb.com/sequencing-technology/agbt-illumina-provides-additional-details-project-firefly#.Xa8fIehKjb0|work=genomeweb.com }} In 2018, Illumina launched iSEQ, a new product developed using Avantome’s CMOS sensor approach combined with nanowell technology; iSEQ delivered on the original Avantome goals of low cost instrumentation and reduced per-sample processing cost in a long read format.{{cite news |author= |title=Illumina Launches Semiconductor Sequencer, Partners With Thermo Fisher, Releases Prelim Earnings |url=https://www.genomeweb.com/sequencing/illumina-launches-semiconductor-sequencer-partners-thermo-fisher-releases-prelim-earnings#.Xa8nVuhKjb0 |work=genomeweb.com|date= 9 Jan 2018}}

= [[Guardant Health]] =

In 2012, Eltoukhy and AmirAli Talasaz co-founded Guardant Health, established to "forge a new frontier" in cancer detection and treatment using artificial intelligence{{cite magazine |last=Medeiros |first=Joao |date=7 Feb 2019 |title=How SoftBank ate the world: Led by the charismatic Masayoshi Son, Japanese conglomerate SoftBank's Vision Fund is taking over tech, one company at a time. This is the story of what happens if the disruptors are disrupted. |url=https://www.wired.co.uk/article/softbank-vision-fund |magazine=Wired |access-date=25 Oct 2019 }} and a big data approach.{{cite news |last=Leuty |first=Ron |date=11 May 2017 |title=Blood money: Peninsula liquid biopsy company gets $360M injection |url=https://www.bizjournals.com/sanfrancisco/news/2017/05/11/blood-money-peninsula-liquid-biopsy-company-gets.html |work=San Francisco Business Times |access-date=3 Nov 2019 }}{{cite web |url=https://www.fiercebiotech.com/medical-devices/blood-based-liquid-biopsies-are-new-frontier-cancer-diagnosis |title=Blood-based liquid biopsies are the new frontier in cancer diagnosis |author= |date= 20 Jul 2015|website=fiercebiotech.com |publisher=Questex, LLC |access-date=20 Oct 2019 }} They developed new methods to detect and monitor the low levels of circulating tumor DNA (ctDNA) fragments released into the bloodstream of people who have cancer, enabling cancer detection and monitoring using minimally-invasive blood tests (liquid biopsies) which are lower cost and lower risk compared to traditional tissue biopsies.

Under Eltoukhy’s direction as CEO, Guardant Health raised over one billion dollars (US) in financing,{{cite web |url=https://www.biospace.com/article/-ip3o-kodiak-sciences-and-guardant-health-file-for-ipos/ |title=2 Bay Area Biotechs Launch IPOs Worth a Combined $200 Million |last= Terry|first=Mark |date=10 Sep 2018 |website= biospace.com|publisher=BioSpace |access-date=12 Nov 2019 }}{{cite news |last=Fox |first= Michelle|date=4 Oct 2018 |title=Guardant Health soars almost 70% in first day of trading|url=https://www.cnbc.com/2018/10/04/guardant-health-soars-80percent-in-first-day-of-trading.html |work=CNBC |location=USA |access-date=12 Nov 2019 }} launched three products, established collaborations with oncology researchers, and gained recognition as a healthcare innovator in liquid biopsy approaches used for cancer diagnosis and research.{{cite news |last=Cha |first=Ariana Eunjung |date=28 Apr 2016 |title= There's a new sheriff in town in Silicon Valley — the FDA |url=https://www.washingtonpost.com/news/to-your-health/wp/2016/04/28/theres-a-new-sheriff-in-town-in-silicon-valley-the-fda/ |newspaper=The Washington Post |location=San Francisco, CA, USA |access-date=20 Oct 2019 }}{{cite web |url=https://xconomy.com/san-francisco/2014/09/19/forum-highlights-innovators-working-in-global-public-interest/ |title= Forum Highlights Innovators Working in Global Public Interest|last=Tansey |first=Burnadette |date=19 Sep 2014 |website= xconomy.com|publisher=Xconomy, Inc. |access-date=24 Oct 2019 }}{{cite news |last=Leuty |first=Ron |date=22 Jan 2015 |title=9 potential life science IPOs to watch |url=https://www.bizjournals.com/sanfrancisco/blog/biotech/2015/01/ipo-aduro-zosana-avinger-carbylan-cardiodx-invitae.html |work=San Francisco Business Times |location=USA |access-date= 25 Oct 2019}} Named as a World Economic Forum Technology Pioneer and to Fierce Biotech's Fierce 15 list.{{cite web |url=https://www.fiercebiotech.com/topic/fiercemedtech-fierce-15-2017 |title=FierceMedTech's Fierce 15, 2017 |last=Al Idius |first=Amirah|date=11 Dec 2017 |website=Fiercebiotech.com |publisher=Questex, LLC }} In 2014 the company launched Guardant360, the first commercially available comprehensive liquid biopsy for cancer.{{cite news |last=Hay |first=Timothy |date=17 Jul 2015 |title=Liquid Biopsy the Key to 'Active Surveillance' of Cancer, Guardant Health Says |url=https://blogs.wsj.com/venturecapital/2015/07/17/liquid-biopsy-the-key-to-active-surveillance-of-cancer-guardant-health-says/ |work=The Wall Street Journal |location=USA |access-date=18 Oct 2019 }}{{cite news |last=Sawers |first=Paul |date=11 May 2017 |title=Cancer screening firm Guardant Health raises US$360 million to sequence tumor DNA of 1 million patients |url=https://venturebeat.com/2017/05/11/cancer-screening-startup-guardant-health-raises-360-million-to-sequence-tumor-dna-of-1-million-patients/ |work=VentureBeat |location=USA |access-date=22 Oct 2019 }}{{cite web |url=https://www.technologyreview.com/s/538646/why-liquid-biopsies-in-cancer-treatment-are-still-experimental/ |title= The Great Cancer Test Experiment |first=Antonio |last = Regalado |date=24 Jun 2015 |website=MIT Technology Review|publisher= MIT|access-date= 12 Oct 2019}} The test uses a combination of genomics and signal processing innovations to simultaneously profile the mutational signature of several {{small|(54 at time of product launch; 74 as of 2019)}}{{cite news |last=Harper |first= Matthew|date=12 Nov 2018 |title=A $3 Billion Startup's Shares Gain On Hopes For A Cancer Blood Test |url=https://www.forbes.com/sites/matthewherper/2018/11/12/a-3-billion-startups-shares-gain-on-hopes-for-a-cancer-blood-test/#17ebf6853ab6 |work=Forbes |access-date= 11 Nov 2019}} circulating tumor DNA genes in patient blood samples.{{cite book|author1=Arun Rao|author2=Piero Scaruffi|title=A History of Silicon Valley: The Greatest Creation of Wealth in the History of the Planet|url=https://books.google.com/books?id=UjI8nQEACAAJ|access-date=8 November 2019|year=2013|publisher=Omniware Group|isbn=978-1-4903-3040-2}} By 2016, the test was in use by oncologists to guide personalized treatment plans for late-stage cancer patients,{{cite news |last=Philippidis |first=Alex |date= 27 Mar 2019|title=Five-Year Super Successes in Genomics and Precision Medicine |url=https://www.clinicalomics.com/magazine-editions/volume-6-issue-number-2-march-april-2019/five-year-super-successes/ |work=ClinicalOmics |access-date=8 Nov 2019 }} and to pair advanced cancer patients with clinical trial opportunities.{{cite web |url= https://www.modernhealthcare.com/article/20160820/MAGAZINE/308209978/innovations-startup-s-liquid-biopsies-match-cancer-patients-with-trials | title= Innovations: Startup's liquid biopsies match cancer patients with trials |last=Teichert |first=Erica |date=20 Aug 2016 |website= Modern Healthcare|publisher=Crain Communications|access-date= 22 Oct 2019}} The Food and Drug Administration granted Guardant360 Expedited Access Pathway status in 2018.{{cite web |website=fdanews.com |title=FDA Grants EAP Designation to Guardant's NGS-Based Liquid Biopsy |author= |date= 22 Feb 2018|url=https://www.fdanews.com/articles/185711-fda-grants-eap-designation-to-guardants-ngs-based-liquid-biopsy |publisher=FDA News |access-date=10 Nov 2019 }} GuardantOMNI, an expanded testing panel measuring levels of 500 circulating tumor DNA (ctDNA) genes, was launched in 2017.{{cite news |last=Philippidis |first=Alex |date=14 Jan 2019 |title=Guardant Health Launches Blood-Based Early Cancer Assay for Research Use |url=https://www.genengnews.com/news/guardant-health-launches-blood-based-early-cancer-assay-for-research-use/ |work=Genetic Engineering and Biotechnology News |publisher=Mary Ann Liebert |access-date=6 Nov 2019 }} Released for research use in 2019, LUNAR is an assay for high sensitivity detection of changes in genomic and epigenetic signatures of ctDNA in early stage and recurring cancers.{{cite web |url=https://www.genomeweb.com/business-news/jp-morgan-healthcare-day-2-thermo-fisher-exact-sciences-guardant-hologic-caris-and#.XcM-w-hKjb0 |title=JP Morgan Healthcare, Day 2: Thermo Fisher, Exact Sciences, Guardant, Hologic, Caris, and More |first=Leo |last=O'Connor |date=9 Jan 2019 |access-date=6 Nov 2019 }}

In 2017, a venture capital funding round led by SoftBank raised $360 million, allowing Guardant Health to expand operations globally{{cite news |last1=Baker|last2=Roumeliotis|first2=Greg |first1=Liana |date=19 May 2017 |url=https://www.reuters.com/article/us-softbank-visionfund/dealmakers-aplenty-softbanks-son-looks-for-wonks-idUSKCN18F0FS |title=Dealmakers aplenty, SoftBank's Son looks for wonks |work=Reuters |access-date=25 Oct 2019 }} and continue to focus on accelerating progress towards early cancer detection.{{cite web |url=https://www.biospace.com/article/guardant-s-liquid-biopsy-trial-hits-primary-endpoint-for-lung-cancer/ |title=Guardant Health's Liquid Biopsy Wins in Head-to-Head Trial in Lung Cancer|last=Terry |first=Mark |date=28 Feb 2019 |website=biospace.com |access-date=3 Oct 2019 }} Eltoukhy and Talasaz rang the opening bell at the Nasdaq when Guardant Health went public (IPO) on October 4, 2018.{{cite news |author= |title=Opening Bell, October 4, 2018: Ringing today's opening bells are Mateusz Morawiecki, Republic of Poland prime minister, at the NYSE, and Guardant Health with CEO Helmy Eltoukhy and President AmirAli Talasaz at the Nasdaq. |url=https://www.cnbc.com/video/2018/10/04/opening-bell-october-4-2018.html |work=CNBC |date= 4 Oct 2018|access-date=18 Oct 2019 }} In January 2019, Guardant Health entered a partnership with pharmaceutical company AstraZeneca to develop companion diagnostics.{{cite web |url=https://www.fiercebiotech.com/medtech/guardant-s-blood-test-tracks-microsatellite-instability-status-par-tissue-biopsy-new-study |title=Guardant's blood test tracks microsatellite instability status on par with tissue biopsy in new study |last=Hale |first=Connor |website=FierceBiotech |publisher= Quantex, LLC|access-date=25 Oct 2019 }}{{cite web |url=https://www.genomeweb.com/molecular-diagnostics/guardant-health-develop-blood-based-cdx-astrazeneca-drugs#.Xci-MjNKjb0 |title=Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs |author= |date= 13 Dec 2018|website=genomeweb.com |publisher=GenomeWeb |access-date=10 Nov 2019 }} In October 2019, the company initiated ECLIPSE, a 10,000 patient colorectal cancer study, in an effort to evaluate the effectiveness of using blood tests to screen for colorectal cancer in the general population.{{cite news |last=Lovelace |first=Berkeley Jr.|date= 3 Jun 2019|title=We're not far from using blood tests to detect early-stage cancer, says CEO of Silicon Valley oncology firm |url= https://www.cnbc.com/2019/06/03/not-far-from-blood-tests-to-detect-early-cancer-silicon-valley-ceo.html|work= CNBC|access-date=15 Oct 2019 }}{{cite web |url=https://www.onclive.com/web-exclusives/pivotal-study-examines-blood-test-as-crc-screening-method |title=Pivotal Study Examines Blood Test as CRC Screening Method |last=Columbus |first=Gina |date=24 Oct 2019|website=onclive.com |publisher=Intellisphere, LLC |access-date=12 Nov 2019 }}

Eltoukhy was named to Time Magazine’s inaugural 50 Most Influential People in Healthcare (2018){{cite magazine |author= |date=18 Oct 2018 |title=The Health Care 50: The 50 most influential people in health care (2018) |url=https://time.com/5420604/how-we-chose-2018-influential-people-in-healthcare/ |magazine=Time |access-date=25 Oct 2019}}{{cite magazine |author= |date=18 Oct 2018 |title=The Health Care 50: The 50 most influential people in health care (2018) - Helmy Eltoukhy and AmirAli Talasaz |url=https://time.com/collection/health-care-50/5425093/helmy-eltoukhy-and-amirali-talasaz/ |magazine=Time |access-date=25 Oct 2019}} and Fortune’s 40 under 40 (2017).{{cite news |author= |date=2017 |title=Fortune's 40 under 40 (2017) |work=Fortune |url=https://fortune.com/40-under-40/2017/helmy-eltoukhy-and-amirali-talasaz/ |access-date=22 Oct 2019}}{{cite web |author= |date=2017 |title=Fortune Magazine – Guardant Health CEO And President On This Year's "40 Under 40" List |url=https://califesciences.org/fortune-magazine-guardant-health-ceo-president-years-40-40-list/ |access-date=21 Oct 2019 |website=califesciences.org |publisher=California Life Sciences Association}}

Representative publications

=Journal articles=

  • El Gamal A and Eltoukhy H (2005) CMOS image sensors. IEEE Circuits and Devices Magazine 21(3), 6-20{{cite journal |last1=El Gamal |first1=A |last2=Eltoukhy |first2= H|date=2005 |title= CMOS image sensors|url=http://isl.stanford.edu/groups/elgamal/abbas_publications/M001.pdf |journal=IEEE Circuits and Devices Magazine |volume=21 |issue=3 |pages= 6–20|doi= 10.1109/MCD.2005.1438751|s2cid=8813059 |access-date= 9 Nov 2019}}
  • Eltoukhy H et al. (2006) A 0.18-/spl mu/m CMOS bioluminescence detection lab-on-chip. IEEE Journal of Solid-State Circuits 41(3){{cite journal |last1=Eltoukhy |first1=H |last2=Salama |first2=K|last3=El Gamal |first3=A |date=March 2006 |title=A 0.18-/spl mu/m CMOS bioluminescence detection lab-on-chip |journal=IEEE Journal of Solid-State Circuits |volume=41 |issue=3 |doi=10.1109/JSSC.2006.869785 |s2cid=12890520 }}
  • Lanman et al. (2015) Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLOS One {{PMID|26474073}}{{cite journal |date=16 Oct 2015 |title=Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA |journal=PLOS One |volume= 10|issue= 10|pages= e0140712|doi= 10.1371/journal.pone.0140712|pmid=26474073 |pmc=4608804 |first1=Richard B.|last1= Lanman |first2=Stefanie A. |last2= Mortimer |first3=Oliver A.|last3= Zill |first4=Dragan| last4=Sebisanovic |first5=Rene|last5= Lope|first6=Sibel |last6=Blau |first7=Eric A.|last7= Collisson|first8=Stephen G|last8=Divers|first9=Dave S. B. |last9=Hoon|first10=E. Scott |last10=Kopetz|first11=Jeeyun |last11=Lee|first12=Petros G. |last12=Nikolinakos|first13=Arthur M. |last13=Baca |first14=Bahram G.|last14=Kermani|first15=Helmy |last15=Eltoukhy |first16=AmirAli |last16=Talasaz |bibcode=2015PLoSO..1040712L |doi-access=free }}
  • Odegaard J et al. (2018) Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clinical Cancer Research 24(15) 3539-3549.{{PMID| 29691297}}
  • Zill OA et al. (2018) The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clinical Cancer Research 24(15), 3528-3538 {{PMID|29776953}}

=Patents=

  • Engineered luciferases, (2009).{{cite patent |country=US|number=2009286299|status=application|title=Engineered luciferases|pubdate=2009-11-19|inventor1-last=Ronaghi|inventor1-first=Mostafa|inventorlink1=Mostafa Ronaghi|inventor2-last=Eltoukhy|inventor2-first=Helmy|inventor3-first=Leila|inventor3-last=Bazargan}}
  • Biological analysis arrangement and approach therefor, (2012).{{cite patent |country=US|number=8313904|title=Biological analysis arrangement and approach therefor|pubdate=2012-11-20|inventor1-last=El Gamal|inventor1-first=Abbas|inventorlink1=Abbas El Gamal|inventor2-first=Helmy|inventor2-last=Eltoukhy|inventor3-first=Khaled |inventor3-last=Salama|assign1=The Board of Trustees of the Leland Stanford Junior University & inventors.}}
  • Multibase delivery for long reads in sequencing by synthesis protocols, (2012).{{cite patent |country=US|number=8236532|title=Multibase delivery for long reads in sequencing by synthesis protocols|pubdate=2012-08-07|inventor1-last=Ronaghi|inventor1-first=Mostafa|inventorlink1=Mostafa Ronaghi|inventor2-last=Eltoukhy|inventor2-first=Helmy|assign1=Illumina, Inc. & inventors.}}
  • Methods and systems for detecting genetic variants, (2015).{{cite patent |country=EP |number=3087204 |status= |title=Methods and systems for detecting genetic variants|pubdate=2015-07-15|inventor2-first=AmirAli|inventor2-last=Talasaz|inventor1-first=Helmy|inventor1-last=Eltoukhy|assign=Guardant Health, Inc.}}
  • Methods to detect rare mutations and copy number variation, (2016).{{cite patent |country=EP|number=2893040|status= |title=Methods to detect rare mutations and copy number variation|pubdate=2016-11-02|inventor2-first=Helmy|inventor2-last=Eltoukhy|inventor1-first=AmirAli|inventor1-last=Talasaz|assign=Guardant Health Inc.}}
  • Methods for multi-resolution analysis of cell-free nucleic acids, (2017).{{cite patent |country=US|number=9850523|title=Methods for multi-resolution analysis of cell-free nucleic acids|pubdate=2017-12-26|inventor1-first=Darya|inventor1-last=Chudova|inventor2-first=Helmy|inventor2-last=Eltoukhy|inventor3-first=Stefanie Ann Ward|inventor3-last=Mortimer|inventor4-first=Diana|inventor4-last=Abdueva|assign=Guardant Health Inc.}}

Personal life

Helmy Eltoukhy was born and raised in the San Francisco Bay Area. He is currently in the process of legally dissolving his marriage to Carson Eltoukhy. Carson filed for divorce on September 18, 2020, in the San Mateo County Superior Courts. The case, presided over by multiple judges, including Sharon K. Cho, Don R. Franchi, and Susan Greenberg, remains active with pending matters as of the latest update in October 2024. The dissolution proceedings address matters involving minor children, as noted in the docket entries. Both Carson and Helmy Eltoukhy are represented by their respective attorneys, who continue to navigate the complexities of this family court case as they work towards finalizing the separation.{{Cite web |title=CARSON ELTOUKHY vs. HELMY ELTOUKHY |url=https://unicourt.com/case/ca-sm-carson-eltoukhy-vs-helmy-eltoukhy-764042 |access-date=2024-11-12 |website=UniCourt |language=en}}

=Sports ownership=

In December 2024, Eltoukhy was announced as co-Chairman of English football club Sheffield United alongside fellow American businessman Steve Rosen. The club was taken over by the consortium group COH Sports led by Eltoukhy and Rosen.{{cite web | url=https://www.sufc.co.uk/news/2024/december/23/coh-sports-completes-blades-acquisition/ | title=COH Sports completes Blades acquisition | date=December 23, 2024 | access-date=January 20, 2025 |website=sufc.co.uk}}

Recognition

Eltoukhy was named to Time Magazine’s inaugural 50 Most Influential People in Healthcare in 2018, Fortune’s 40 under 40 in 2017, and the San Francisco Business Times 40 under 40 in 2019.{{cite web |url=https://www.eventa.us/events/san-francisco-ca/40-under-40-awards-51604935 |title=40 Under 40 Awards |author= |date=2019 |website=evanta.us |publisher=eventa.us |access-date= 25 Oct 2019}} He has served as an invited speaker or panelist at the World Economic Forum,{{cite web |url= http://www3.weforum.org/docs/AMNC14/WEF_AMNC14_ScienceTechnology_Brochure.pdf |title=Convening Innovators from the Science and Technology Communities |author= |date=2014 |website=weforum.org |publisher=World Economic Forum |access-date=22 Oct 2019}} Fortune Brainstorm Health 2017,{{cite web |url=https://fortune.com/2017/05/03/cancer-blood-test-liquid-biopsy/ |title= This Simple Cancer Test Comes With a Big Caveat|last=Mukhurjee |first=Sy |date= 3 May 2017|website= Fortune|publisher=Fortune Media IP Limited |access-date= 22 Oct 2019}} The Business of Personalized Medicine Summit 2018,{{cite web |url=http://www.personalizedmedicinesummit.com/speakers.html |title=The Business of Personalized Medicine |author= |date=2018 |website= personalizedmedicinesummit.com|publisher= BPM Summit|access-date=2 Oct 2019 }}{{cite web |url=http://www.discoveriesinhealthpolicy.com/2018/10/very-brief-blog-bay-area-business-of.html |title=Very Brief Blog: Bay Area "Business of Personalized Medicine Summit" - December 6, 2018 |author= |date=2018 |website= discoveriesinhealthpolicy.com|publisher=Discoveries in Health Policy: Ideas for or from an evolving healthcare system |access-date= 6 Nov 2019 }} HLTH (healthcare innovation) 2018,{{cite web |url=https://www.thekennedyforum.org/hlth-announces-first-150-senior-healthcare-executive-speakers-including-100-ceos-and-founders-and-first-30-sponsoring-companies/ |title= HLTH Announces First 150+ Senior Healthcare Executive Speakers, Including 100+ CEOs and Founders |author= |date= 5 Oct 2017 |website=thekennedyforum.org |publisher=The Kennedy Forum |access-date=5 Oct 2019 }} and the World Medical Innovation Forum 2016.{{cite web |url=https://neuroscienceinnovationforum.org/wp-content/uploads/2016/03/2016-World-Medical-Innovation-Forum-BROCHURE-3-6-16.pdf |archive-url=https://web.archive.org/web/20191106232455/https://neuroscienceinnovationforum.org/wp-content/uploads/2016/03/2016-World-Medical-Innovation-Forum-BROCHURE-3-6-16.pdf |url-status=usurped |archive-date=November 6, 2019 |title=World Medical Innovation Forum 2016 |author= |date=2016 |website=neuroscienceinnovationforum.org |publisher=World Medical Innovation Forum |access-date=3 Oct 2019 }}

References

{{Reflist}}